Just that the stock was $21 in Feb 2019 before the news of Teprotnamab thyroid drug potential. The stock went up 40% very quickly in Febuary, and has essentially been flat since. I don't see a catalyst that will push this over $30 till Teprotunamab gets approval, and some analysts give additional revenue estimates. That won't be till April or later. Till then, I see no catalyst.
Market Data 
Markets 
AI
